Literature DB >> 18506926

Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital.

Yolanda Faia Manhaes Tolentino1, Homero Soares Fogaca, Cyrla Zaltman, Lia Laura Lewis Ximenes, Henrique Sergio Moraes Coelho.   

Abstract

AIM: To evaluate the prevalence of hepatitis B virus (HBV) infection in inflammatory bowel disease (IBD) patients that followed up in our hospital and try to identify the possible risk factors involved in this infection transmission.
METHODS: This was a cross-sectional study for which 176 patients were selected according to their arrival for the medical interview. All these patients had already IBD diagnosis. The patient was interviewed and a questionnaire was filled out.
RESULTS: In the group of 176 patients whom we examined, we found that 17% (30) were anti-HBc positive. Out of 30 patients with positive anti-HBc, 2.3% (4) had positive HBsAg and negative HBV-DNA. In an attempt to identify the possible HBV infection transmission risk factors in IBD patients, it was observed that 117 patients had been submitted to some kind of surgical procedure, but only 24 patients had positive anti-HBc (P = 0.085). It was also observed that surgery to treat IBD complications was not a risk factor for HBV infection transmission, since we did not get a statically significant P value. However, IBD patients that have been submitted to surgery to treat IBD complications received more blood transfusions then patients submitted to other surgical interventions (P = 0.015).
CONCLUSION: There was a high incidence of positive anti-HBc (17%) and positive HBsAg (2.3%) in IBD patient when compared with the overall population (7.9%).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18506926      PMCID: PMC2712853          DOI: 10.3748/wjg.14.3201

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

Review 1.  Barriers to accessing and accepting dental care.

Authors:  R Freeman
Journal:  Br Dent J       Date:  1999-07-24       Impact factor: 1.626

2.  Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen.

Authors:  H Marusawa; S Uemoto; M Hijikata; Y Ueda; K Tanaka; K Shimotohno; T Chiba
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

3.  Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?

Authors:  Gunda Millonig; Michaela Kern; Othmar Ludwiczek; Karin Nachbaur; Wolfgang Vogel
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

Review 4.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.

Authors:  R P Perrillo
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

5.  Surgical procedures as a major risk factor for chronic hepatitis C virus infection in Italy: evidence from a case-control study.

Authors:  G B Gaeta; T Stroffolini; G Taliani; F M Ippolito; G Giusti; C De Bac
Journal:  Int J Infect Dis       Date:  1999       Impact factor: 3.623

6.  Contamination with hepatitis B virus DNA in gastrointestinal endoscope channels: risk of infection on reuse after on-site cleaning.

Authors:  Y Ishino; K Ido; K Sugano
Journal:  Endoscopy       Date:  2005-06       Impact factor: 10.093

7.  [Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors].

Authors:  F Longo; X Hebuterne; A Tran; P Staccini; P Hastier; S Schneider; S Benzaken; C Tirtaine; P Rampal
Journal:  Gastroenterol Clin Biol       Date:  2000-01

Review 8.  Hepatitis B: an important public health issue.

Authors:  W C Maddrey
Journal:  J Med Virol       Date:  2000-07       Impact factor: 2.327

9.  Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm.

Authors:  U Broomé; H Glaumann; G Hellers; B Nilsson; J Sörstad; R Hultcrantz
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

10.  Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis.

Authors:  M Cottone; A Magliocco; G Trallori; C Brignola; C Vandelli; S Ardizzone; G Meucci; F Zannoni; G Di Maio; M Astegiano
Journal:  Ital J Gastroenterol       Date:  1995 Jan-Feb
View more
  15 in total

Review 1.  What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

Authors:  Gianluca Andrisani; Alessandro Armuzzi; Manuela Marzo; Carla Felice; Daniela Pugliese; Alfredo Papa; Luisa Guidi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

2.  Hepatitis B vaccination in patients with inflammatory bowel disease.

Authors:  Ruwaida Ben Musa; Anuhya Gampa; Sanjib Basu; Ali Keshavarzian; Garth Swanson; Michael Brown; Rana Abraham; Keith Bruninga; John Losurdo; Mark DeMeo; Sohrab Mobarhan; David Shapiro; Ece Mutlu
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

Review 3.  Updates in vaccination: recommendations for adult inflammatory bowel disease patients.

Authors:  Khadija Chaudrey; Michelle Salvaggio; Aftab Ahmed; Sultan Mahmood; Tauseef Ali
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

Review 4.  Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.

Authors:  Pilar López-Serrano; Jose Lázaro Pérez-Calle; Maria Dolores Sánchez-Tembleque
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

5.  Prevalence and influences of hepatitis B virus infection on inflammatory bowel disease: a retrospective study in southern China.

Authors:  Yao He; Pingping Xu; Yujun Chen; Rongping Yang; Baili Chen; Zhirong Zeng; Minhu Chen
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 6.  Vaccination in Patients with Inflammatory Bowel Diseases.

Authors:  Christine N Manser; Michel H Maillard; Gerhard Rogler; Philipp Schreiner; Florian Rieder; Silja Bühler
Journal:  Digestion       Date:  2020-01-22       Impact factor: 3.216

Review 7.  Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease.

Authors:  Stefano Sansone; Maria Guarino; Fabiana Castiglione; Antonio Rispo; Francesco Auriemma; Ilaria Loperto; Matilde Rea; Nicola Caporaso; Filomena Morisco
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

8.  Evaluation of factors associated with response to hepatitis B vaccination in patients with inflammatory bowel disease.

Authors:  Cem Cekic; Fatih Aslan; Adnan Kirci; Zeynep Zehra Gümüs; Mahmut Arabul; Elif Sartas Yüksel; Sezgin Vatansever; Süreyya Gül Yurtsever; Emrah Alper; Belks Ünsal
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

Review 9.  Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment.

Authors:  Georgios Axiaris; Evanthia Zampeli; Spyridon Michopoulos; Giorgos Bamias
Journal:  World J Gastroenterol       Date:  2021-07-07       Impact factor: 5.742

Review 10.  Update on Vaccinating the Patient With Inflammatory Bowel Disease.

Authors:  Jennifer Coukos; Francis A Farraye
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.